DBDavide Brancato

Davide Brancato

*This is an algorithmically generated author record based on publicly available information.

Davide Brancato has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-term GLP-1 receptor agonist therapy in obesity: expert panel recommendations for good clinical practice

    by Davide Brancato, Giorgio Borretta, Marco Chianelli, Olga Disoteo, Marco Grasso, Franco Grimaldi, Edoardo Guastamacchia, Fabrizio Muratori, Salvatore Oleandri, Marcello Orio, et al.

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as highly effective therapies for obesity, facilitating weight loss and improving cardiometabolic risk factors. However, several challenges persist regarding optimal long-term management in real-world clinical practice. A board of clinicians with expertise in obesity and metabolic diseases discussed practical recommendations for the sustainable long-term management of GLP-1RA therapy. Key themes included the maintenance of clinical benefits, prevention of weight regain, treatment sustainability, and long-term safety and tolerability. The panel highlighted the necessity of approaching obesity as a chronic, relapsing disease requiring long-term therapeutic strategies. Comprehensive baseline phenotyping and a treat-to-benefit approach were identified as essential for defining clinically meaningful treatment targets beyond weight loss alone. Maintenance therapy after achievement of initial outcomes, flexible dose management, and early recognition of relapse signals were considered essential for preserving benefits and preventing weight regain. Pharmacotherapy should be integrated within a multimodal care model that includes nutritional counseling, physical activity, and behavioral support, while addressing real-world barriers such as economic sustainability. Proactive management of adverse events and patient education were recognized as critical for ensuring long-term adherence. Sustainable use of GLP-1RA therapy requires integrated, patient-centered management strategies that combine pharmacological treatment with lifestyle interventions and pragmatic dose adjustment. Future collaborative real-world data initiatives may further refine these practical recommendations and help optimize long-term obesity care.

  • Open Access

    Permanence of Cognitive Alterations in Post- and Long COVID Patients: Glia and Brain Alteration, Gender Differences and New Diabetes Diagnosis

    by Concetta Mezzatesta, Davide Brancato, Francesca Provenzano, Simone Marchese, Maria Luisa Savona, Sara Bazzano, Rosa Gesualdo, Francesco Cannia, Angela Eleonora Porcino, Mario Tambone Reyes, et al.

    Background: COVID-19 has been associated with multisystemic sequelae, including persistent neurocognitive impairment and emerging metabolic alterations. Growing evidence suggests that glial dysfunction and inflammation may play a pivotal role in both cognitive decline and new-onset diabetes following SARS-CoV-2 infection. Objectives: This study aimed to assess the prevalence and characteristics of cognitive impairments in post-COVID-19 patients and to explore their correlation with new-onset diabetes, neuroanatomical changes, and psychological symptoms, with a specific focus on gender differences. Methods: A total of 245 patients (mean age 56.8 ± 12 years), previously diagnosed with COVID-19, were enrolled between April 2021 and August 2023. Participants underwent a comprehensive neuropsychological assessment (MMSE, Rey-Osterrieth Figure, FAB, Hamilton, STAI, IES-R), structured interviews, and, in a subset, brain MRI. Individuals with pre-existing neurological disorders were excluded. Data were analyzed for cognitive performance, neuroimaging abnormalities, and metabolic outcomes, including new-onset diabetes. Results: Cognitive dysfunction was identified in 87% of participants: mild in 47%, moderate in 21.6%, and severe in 10.8%. Glial alterations on MRI were observed in 51%, hippocampal atrophy in 9%, and temporal lobe reduction in 4%. Notably, 12% of patients developed new-onset diabetes post-COVID, of whom 80% exhibited mild to moderate cognitive deficits. Depressive symptoms were present in 80.9%, and anxiety in 93.5%, with significantly higher incidence in female patients. PTSD symptoms correlated with greater cognitive impairment. Ongoing research into the mechanisms underlying these persistent cognitive impairments in subjects with and without types 1 and 2 diabetes. This paper presents the final data of the research published in the previous article referenced in the bibliography. Conclusions: This study highlights a significant association between cognitive decline and new-onset diabetes in post-COVID patients, likely mediated by systemic inflammation and glial dysfunction. Particularly noteworthy are the findings of neuroanatomical alterations, including nonspecific glial signal changes, hippocampal atrophy, and temporal lobe volume reductions, suggesting post-infectious cerebral vulnerability with potential long-term consequences. These results support the need for integrating cognitive screening, brain neuroimaging, and metabolic monitoring into post-COVID care pathways—especially for women and individuals presenting with anxiety or depressive symptoms. An early and interdisciplinary approach is essential to address the neuro-metabolic and cerebral sequelae of long COVID.

  • Open Access

    Management of Hypothyroidism in Internal Medicine: Patient Profile and Effects of an Educational Programme in the Cluster-Randomized FADOI TIAMO Study

    by D. Brancato, B. Biondi, T. M. Attardo, A. Fierro, M. Nizzoli, R. Vettor, E. Monaco, R. Romano, V. Ariete, C. Usai, et al.

    Background and aims: There is still limited knowledge regarding the clinical profile and appropriateness of treatment in patients with hypothyroidism hospitalized in Internal Medicine (IM) Departments in Italy. The aim of this study is to evaluate: 1) the characteristics of patients and possible deviations from national and international clinical practice recommendations (CPRs) in evidence-based guidelines (EBGs); 2) the improvement of patient management by means of a standardized educational programme (EP). Methods: A nationwide multicentre study, comprising two replications of a retrospective survey (phases 1 and 3) with an intervening EP (phase 2) in half of the centres and no EP in the other half, was conducted. The EP was based on outreach visits. Centres were assigned to the two arms of the study, labelled the training group (TG) and control group (CG) respectively, by cluster randomization. Four EBGs and 39 CPRs provided the basis on which 22 treatment management indicators were identified (7 referring to the time of hospital admission, 15 to post-admission). Results: The 21 participating centres recruited 587 hospitalized patients with hypothyroidism, 421 of which were females (71.7%, mean age 74.1 + 14.4 yrs): 318 in phase 1 and 269 in phase 3. The cause of hypothyroidism was unknown in 282 patients (48%). Evaluation at the time of admission identified satisfactory adherence to CPRs (>50%) for 63.6% of the indicators. In the phase 3, TG centres showed significant improvement vs CG in 4 of the 15 post-admission indicators, while 1 out of 15 was significantly worse. Conclusions: The EP based on outreach visits significantly improved some indicators in the management of patients with hypothyroidism, with specific reference to appropriateness of TSH dosage and levothyroxine (LT4) treatment modality. Clinical Trial Registration: ClinicalTrials.gov, identifier NCT05314790.


  • Open Access

    Longitudinal investigation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in older patients in the province of Palermo (Southern Italy) during the early wave of the pandemic

    by Domenica Matranga, Laura Maniscalco, Marco Enea, Dario De Luca, Davide Brancato, Emanuele La Spada, Alessandro Scorsone, Paola Di Carlo

    Introduction: Clinical presentation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in old adults from southern-Italy is little known. This study aims to investigate the mortality risk related to risk factors, therapy and clinical course and to suggest prognostic...


  • Open Access

    L’internista ospedaliero nella gestione del paziente diabetico complesso

    by L Magnani, G Beltramello, D Brancato, Andrea Fontanella, Roberto Nardi, Dario Manfellotto, Mauro Campanini, Paola Gnerre, Francesco D'Amore, Giancarlo Agnelli, et al.

    L’internista deve occuparsi (e rioccuparsi) del paziente diabetico complesso in Ospedale A. Fontanella, L. Magnani Diagnosi, classificazione, epidemiologia clinica del diabete mellito V. Provenzano, D. Brancato Up-date degli studi disponibili P. Gnerre, T.M. Attardo, A. Maffettone, G. Beltramello Il diabete mellito costituisce ancora un equivalente di rischio cardiovascolare? G. Augello, T.M. Attardo Le terapie del diabete tipo 2 sono tutte uguali ai fini della riduzione della morbilità e mortalità cardiovascolare? V. Provenzano Le nuove tecnologie nella cura del diabete mellito D. Brancato, V. Provenzano Insuline prandiali e insuline basali R. Pastorelli Quali target nel diabete mellito: il dogma dell’emoglobina glicata è davvero imprescindibile? V. Manicardi Il controllo dell’iperglicemia nel paziente anziano polipatologico: è sempre necessario iniziare l’insulina? G. Gulli, M. Nizzoli La nefropatia diabetica F. Salvati, D. Manfellotto, M. Stornello Cirrosi epatica e diabete M. Imparato, L. Fontanella La terapia personalizzata nel diabete di tipo 2 A. Maffettone, C. Peirce, M. Rinaldi La gestione dell’iperglicemia nel paziente critico e instabile C. Nozzoli La disfunzione erettile nel paziente diabetico di tipo 2 N. Artom, A. Bosio, G. Pinna Quali obiettivi di approccio integrato nella gestione del diabete mellito? E. Romboli, D. Panuccio Iperglicemia, normoglicemia ed ipoglicemia nei pazienti anziani fragili: situazioni a rischio, politerapia e comorbilità A. Greco, M. Greco, D. Sancarlo, F. Addante, G. D’Onofrio, D. Antonacci, S. De Cosmo L’impatto clinico-prognostico dell’ipoglicemia nel paziente ospedalizzato V. Borzì, L. Morbidoni, A. Fontanella L’internista chiamato in consulenza per un diabete gestazionale: quale approccio pragmatico? P. Novati, L. Sali La frugalità nella gestione del diabete mellito: qualità assistenziale, governo clinico e costi correlati P. Gnerre, G. Carta, D. Montemurro La gestione dell’iperglicemia in area medica, ma senza esagerare. L. Magnani, G. Beltramello APPENDICE IUn approccio pragmatico per la valutazione globale e la gestione del paziente diabetico F. Pieralli, A. Crociani, C. Bazzini APPENDICE IILe insuline e i farmaci ipoglicemizzanti orali disponibili P. Zuccheri, L. Alberghini, E. Sora APPENDICE IIILe scale di correzione insulinica: pro e contro V. Borzì


  • The Effectiveness and Durability of an Early Insulin Pump Therapy in Children and Adolescents with Type 1 Diabetes Mellitus

    by Davide Brancato, Mattia Fleres, Vito Aiello, Gabriella Saura, Alessandro Scorsone, Lidia Ferrara, Francesca Provenzano, Anna Di Noto, Lucia Spano, Vincenzo Provenzano

    Background: This study evaluated the predictors of effectiveness and durability of insulin pump therapy in children and adolescents who have initiated continuous subcutaneous insulin infusion (CSII) within 2 years after the diagnosis of type 1 diabetes mellitus (T1DM). Subjects and Methods: The charts of individuals with T1DM using insulin pumps who were treated at our center were reviewed, including subjects with age at onset of P =0.01; R 2 =0.089). A significant reduction of the mean yearly HbA1c from baseline throughout all the follow-up was observed ( P P P =0.004, respectively). Conclusions: The present study suggests that early pump commencement in children and adolescents with T1DM provides lower and more durable HbA1c values than a late commencement. It is possible that an early pump commencement could prolong the honeymoon phase, but we cannot confirm or exclude this hypothesis because the lack of data about C-peptide levels during the follow-up.


  • Prognostic Accuracy of Continuous Glucose Monitoring in the Prediction of Diabetes Mellitus in Children with Incidental Hyperglycemia: Receiver Operating Characteristic Analysis

    by Davide Brancato, Gabriella Saura, Mattia Fleres, Lidia Ferrara, Alessandro Scorsone, Vito Aiello, Anna Di Noto, Lucia Spano, Vincenzo Provenzano

    Aim: The purpose of this study is to evaluate continuous glucose monitoring (CGM) in predicting diabetes mellitus in children with incident hyperglycemia (IH) and negativity for some insular autoantibodies. Subjects and Methods: Thirty-one autoantibody-negative children who presented at our center with IH underwent a baseline assessment and were followed up for 23.8 months (range, 6–48 months). At the end of the follow-up, we compared the receiver operating characteristic (ROC) areas under the curve (AUCs) of metabolic markers from 17 children who developed diabetes (Group A; n =17) and 14 children who did not develop diabetes (Group B; n =14). Results: Only two oral glucose tolerance test (OGTT)-derived markers and three CGM-derived markers showed a good prognostic performance, with ROC AUCs indicating significant results ( P <0.0001) for the following markers: 2-h glucose, OGTT (0.813; 95% confidence interval [CI] 0.621–0.954); AUC glucose, OGTT (0.832; 95% CI 0.611–0.950); CGM glucose measurement peak (0.803; 95% CI 0.621–0.923); percentage of CGM glucose measurements inside the range 70–125 mg/dL (0.866; 95% CI 0.695–0.961); and percentage of CGM measurements ≥126 mg/dL (0.889; 95% CI 0.724–0.973). The combination of the OGTT-derived markers did not increase the predictive value, but the combination of CGM markers with each other or with the OGTT markers yielded higher ROC AUCs (ranging from 0.828 to 0.945). Conclusions: This is the first study showing that CGM is useful in predicting diabetes mellitus in children with IH.


  • Neck Lymph Nodes in Chronic Autoimmune Thyroiditis: The Sonographic Pattern

    by Davide Brancato, Roberto Citarrella, Pierina Richiusa, Marco Calogero Amato, Calogero Vetro, Carla Giordano Galluzzo

    Background: Neck lymph nodes may be involved in the pathogenesis of chronic autoimmune thyroiditis (CAT). This study was undertaken to identify which of the sonographic features of cervical lymph nodes are readily applicable to patients affected by CAT compared to healthy control subjects. Methods: We recruited 106 patients (92 females and 14 males) with CAT and 70 control subjects (53 females and 17 males) without clinical, biochemical, and ultrasonographic evidence of thyroid and neck diseases. We performed laboratory tests (thyrotropin, antithyroperoxidase antibodies, antithyroglobulin antibodies, and ultrasonography) to evaluate in each group: (i) thyroid function, autoimmunity, and morphology; (ii) number, topographic distribution (levels I–VI), and morphology of neck nodes (long-axis diameter; short-axis diameter; short-axis/long-axis ratio; absence or presence of hilus). Results: Total number of neck nodes with long-axis diameter >10 mm was significantly higher in the CAT group than in the control group (mean±standard deviation [SD]: 3.7±2.4 vs. 0.8±1.3; pppppp=0.002) and level IV nodes (3.9±1 vs. 3.1±0.5 mm p=0.030) was increased in CAT patients when compared with healthy controls. Conclusions: The present study is the first one aiming at a systematic description of the sonographic pattern of cervical lymph nodes in CAT. An increased number of benign hyperplastic neck nodes, especially in levels II–IV, appears to be a characteristic sonographic finding associated with CAT.